Regeneron Pharmaceuticals, Inc. (REGN) announced that the European Commission has approved the PD-1 inhibitor Libtayo, or cemiplimab, as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation. This expands the existing EU indication for Libtayo in advanced CSCC to include patients at high risk of disease recurrence.
Libtayo is also currently approved in the EU for the treatment of certain patients with advanced CSCC, advanced basal cell carcinoma, advanced non-small cell lung cancer and recurrent or metastatic cervical cancer.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.